Skip to main content

Xavier Montalban Gairín

I am director of the Multiple Sclerosis Center of Catalonia (Cemcat) at Vall d'Hebron University Hospital since 2007 and Head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Universitat Autònoma de Barcelona (UAB) since 2006 and at Universitat de Vic – Universitat Central de Catalunya (UVic-UCC) since 2021. Additionally, I serve as Senior Consultant in the Department of Neurology at Vall d'Hebron University Hospital.

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

Xavier Montalban Gairín

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

I am director of the Multiple Sclerosis Center of Catalonia (Cemcat) at Vall d'Hebron University Hospital since 2007 and Head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Universitat Autònoma de Barcelona (UAB) since 2006 and at Universitat de Vic – Universitat Central de Catalunya (UVic-UCC) since 2021. Additionally, I serve as Senior Consultant in the Department of Neurology at Vall d'Hebron University Hospital.

I obtained my MD (1983) and PhD (1990) from UAB, specializing in Neurology at Vall d'Hebron University Hospital (1988) and completing my postdoctoral fellowship at St Thomas’ Hospital and the National Hospital for Neurology and Neurosurgery (London). I earned a Diploma in Comprehensive Healthcare Institutions Management from ESADE (2005).

From 2012 to December 2024, I served as Chair of the Neurology Department at Vall d’Hebron University Hospital. Between 2017 and 2020, I was Professor of Medicine and Director of the Division of Neurology at the University of Toronto, as well as Director of the MS Center at St Michael’s Hospital, Toronto.

I am past President (2014-2016) and current Honorary Member of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). I also served as Co-Chair of the Steering Committee of Magnetic Imaging in Multiple Sclerosis (MAGNIMS) and a member of the Steering Committee of the International Progressive MS Alliance. Since December 2024, I have been Vice President of the European Charcot Foundation. Additionally, I chaired the International Advisory Committee on Clinical Trials in MS, sponsored by ECTRIMS and the National Multiple Sclerosis Society (NMSS), until December 2024.

My scientific output includes over 800 peer-reviewed publications, with more than 65,000 citations and a Scopus H-Index of 110 (January 2025). Over the last seven years, I have been among Clarivate’s most cited researchers. I have been Principal Investigator (PI) or collaborator in over 35 competitive projects (€8.5 million) and more than 150 clinical trials.

Notably, I received the 2022 John Dystel Prize (AAN and NMSS), the 2023 Charcot Award (MSIF) for lifetime achievements in MS research, the 2024 Fundación Lilly Award for Biomedical Research, and the 2023 ICS Career Research Award for clinical and scientific excellence.

Projects

Immunogenicity: assesing the clinical relevance and risk minimization of antibodies to biopharmaceuticals. IMI Grant Agreement nº 115303

IP: Manuel Comabella Lopez
Collaborators: Carmen Tur Gomez, Xavier Montalban Gairín, Nicolás Miguel Fissolo
Funding agency: The Innovative Medicines Initiative
Funding: 464328
Reference: ABIRISK_IMI2010
Duration: 01/03/2012 - 27/02/2018

Search for new treatments for multiple sclerosis by means of massive screening of chemical compounds based on gene expressión through the use of connectivity maps

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 96000
Reference: JCI-2011-11491
Duration: 08/06/2012 - 07/06/2015

Ministerio de Ciencia

Búsqueda de biomarcadores en esclerosis múltiple (EM) basada en perfiles de expresión génica mediante ultrasecuenciación

IP: Xavier Montalban Gairín
Collaborators: Sunny Malhotra Sareen
Funding agency: Instituto de Salud Carlos III
Funding: 185130
Reference: PI10/02099
Duration: 01/01/2011 - 31/03/2015

Función de las semaforinas 3A y 7A, moléculas de guía axonal, en la neurodegeneración y la regulación de la respuesta inmunitaria en la encefalomielitis autoinmune experimental

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI10/00456
Duration: 15/09/2010 - 14/09/2014

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Carlota Zabaco Lanfranco

Carlota Zabaco Lanfranco

Administration and Management
Research on Aging, Frailty and Transitions in Barcelona
Read more
Luisa Maria Martinez Sánchez

Luisa Maria Martinez Sánchez

Research assistant
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Maria Emilia Dip Pérez

Maria Emilia Dip Pérez

Research technician
Psychiatry, Mental Health and Addictions
Read more
Marta Sese Faustino

Marta Sese Faustino

Postdoctoral researcher
Translational Molecular Pathology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.